Repligen’s proposed Merger would give each BioLife common share $11.25 in cash and 0.1442 Repligen common shares if the transaction closes. The deal matters to investors because BioLife’s stockholders must approve the merger proposal before the transaction can be completed, with voting set for October 5, 2026.

Key Highlights

  • BioLife stockholders will vote on the merger proposal at a virtual special meeting on October 5, 2026.
  • BioLife had 48,923,333 outstanding common shares eligible for notice and voting as of the September 3, 2026 record date.
  • BioLife’s remaining directors recommended voting for the merger, compensation and adjournment proposals after Tony Hunt recused himself.

Repligen Corp. (NASDAQ: RGEN) would give each BioLife common share $11.25 in cash and 0.1442 Repligen common shares if its proposed merger is completed. The transaction would make BioLife a wholly owned Repligen Subsidiary through a first merger, followed immediately by a second merger involving a Repligen subsidiary.

$11.25 Cash and 0.1442 Repligen Shares

Fractional Repligen shares would not be issued, with cash paid instead for any fractional interest under the merger terms. The BioLife special meeting will take place virtually on October 5, 2026, with stockholders considering the merger proposal, an advisory compensation proposal and an adjournment proposal. The Record Date was September 3, 2026, and 48,923,333 BioLife common shares were outstanding and entitled to vote at the meeting.

Stockholder Approval Required

BioLife’s board, with Tony Hunt recused from deliberations and the vote, determined that the merger agreement and related transactions were fair and in BioLife stockholders’ best interests. The remaining directors unanimously approved the agreement, directed that it be submitted for stockholder approval and recommended voting for all three proposals. BioLife cannot complete the mergers unless stockholders approve the merger proposal. The agreement also remains subject to other conditions that may be satisfied or waived.